excel: 25397
excel with dem: 20383
remove no baseline cre: 18319
remove missing esrd_kt!=0, eGFR_CRE_baseline <10 : 18157
remove missing last_cre_date< ICI_date:17937 (17752 with labs
after ici date)
remove 216 placebo :17721
remove 3 death_date < ici_date(RPDR error): 17718
all
| Characteristic |
N = 2,653 |
| age_ici |
70 (63, 77) |
| male |
|
| 0 |
999 (38%) |
| 1 |
1,654 (62%) |
| Race |
|
| Asian |
106 (4.0%) |
| Black |
165 (6.2%) |
| Other/Unknown |
152 (5.7%) |
| White |
2,230 (84%) |
| Ethnic_Group |
|
| Hispanic |
98 (3.7%) |
| Non_hispanic |
2,386 (90%) |
| Other |
169 (6.4%) |
| ckd_progression |
|
| 0 |
2,540 (98%) |
| 1 |
56 (2.2%) |
| Missing |
57 |
| ckd_incidence |
|
| 0 |
2,442 (94%) |
| 1 |
154 (5.9%) |
| Missing |
57 |
| eskd_composite |
|
| 0 |
2,615 (99%) |
| 1 |
38 (1.4%) |
| ckd_composite |
|
| 0 |
2,420 (91%) |
| 1 |
233 (8.8%) |
| ckd_stage_baseline |
|
| 1 |
947 (36%) |
| 2 |
1,056 (40%) |
| 3 |
584 (22%) |
| 4 |
61 (2.3%) |
| 5 |
5 (0.2%) |
| aki |
|
| 0 |
1,651 (62%) |
| 1 |
1,002 (38%) |
| dm |
|
| 1 |
2,653 (100%) |
| htn |
|
| 0 |
280 (11%) |
| 1 |
2,373 (89%) |
| cad |
|
| 0 |
1,455 (55%) |
| 1 |
1,198 (45%) |
| cirrhosis |
|
| 0 |
2,506 (94%) |
| 1 |
147 (5.5%) |
| cancer_type |
|
| breast |
75 (2.8%) |
| cutaneous / melanoma |
305 (11%) |
| gi |
541 (20%) |
| gu |
416 (16%) |
| gyn |
112 (4.2%) |
| head and neck |
202 (7.6%) |
| heme |
113 (4.3%) |
| neuro |
72 (2.7%) |
| sarcoma |
24 (0.9%) |
| thoracic |
793 (30%) |
| cancer_group |
|
| cutaneous / melanoma |
305 (11%) |
| gi |
541 (20%) |
| gu |
416 (16%) |
| gyn |
112 (4.2%) |
| other |
486 (18%) |
| thoracic |
793 (30%) |
| ace_arb |
|
| 0 |
749 (28%) |
| 1 |
1,904 (72%) |
| diu |
|
| 0 |
765 (29%) |
| 1 |
1,888 (71%) |
| ppi |
|
| 0 |
514 (19%) |
| 1 |
2,139 (81%) |
| steroids |
|
| 0 |
394 (15%) |
| 1 |
2,259 (85%) |
| smoking |
|
| 0 |
1,002 (38%) |
| 1 |
1,651 (62%) |
| Bevacizumab |
|
| 0 |
2,468 (93%) |
| 1 |
185 (7.0%) |
| Cisplatin |
|
| 0 |
2,298 (87%) |
| 1 |
355 (13%) |
| Carboplatin |
|
| 0 |
1,749 (66%) |
| 1 |
904 (34%) |
| Pemetrexed |
|
| 0 |
2,301 (87%) |
| 1 |
352 (13%) |
| Gemcitabine |
|
| 0 |
2,309 (87%) |
| 1 |
344 (13%) |
| Cetuximab |
|
| 0 |
2,579 (97%) |
| 1 |
74 (2.8%) |
| Trastuzumab |
|
| 0 |
2,596 (98%) |
| 1 |
57 (2.1%) |
| VEGF_TKI |
|
| 0 |
2,395 (90%) |
| 1 |
258 (9.7%) |
| statins |
|
| 0 |
576 (22%) |
| 1 |
2,077 (78%) |
| ICI_Class |
|
| PD1 |
1,811 (68%) |
| Combination |
292 (11%) |
| CTLA4 |
100 (3.8%) |
| PDL1 |
450 (17%) |
| nephrotoxic_chemo |
|
| 0 |
1,255 (47%) |
| 1 |
1,398 (53%) |
| pre_CRE_180days |
0.94 (0.74, 1.17) |
| pre_HGB_180days |
11.70 (10.30, 13.10) |
| Missing |
6 |
| pre_ALB_180days |
3.90 (3.50, 4.20) |
| Missing |
15 |
| eGFR_CRE_baseline |
80 (61, 95) |
1year
| Characteristic |
N = 1,261 |
| age_ici |
70 (62, 76) |
| male |
|
| 0 |
482 (38%) |
| 1 |
779 (62%) |
| Race |
|
| Asian |
50 (4.0%) |
| Black |
80 (6.3%) |
| Other/Unknown |
68 (5.4%) |
| White |
1,063 (84%) |
| Ethnic_Group |
|
| Hispanic |
45 (3.6%) |
| Non_hispanic |
1,144 (91%) |
| Other |
72 (5.7%) |
| ckd_incidence_1year |
|
| 0 |
1,202 (95%) |
| 1 |
59 (4.7%) |
| ckd_progression_1year |
|
| 0 |
1,244 (99%) |
| 1 |
17 (1.3%) |
| eskd_composite_1year |
|
| 0 |
1,253 (99%) |
| 1 |
8 (0.6%) |
| ckd_composite_1year |
|
| 0 |
1,181 (94%) |
| 1 |
80 (6.3%) |
| ckd_stage_1year |
|
| 1 |
393 (31%) |
| 2 |
504 (40%) |
| 3 |
329 (26%) |
| 4 |
32 (2.5%) |
| 5 |
3 (0.2%) |
| ckd_stage_baseline |
|
| 1 |
433 (34%) |
| 2 |
516 (41%) |
| 3 |
291 (23%) |
| 4 |
20 (1.6%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
715 (57%) |
| 1 |
546 (43%) |
| dm |
|
| 1 |
1,261 (100%) |
| htn |
|
| 0 |
139 (11%) |
| 1 |
1,122 (89%) |
| cad |
|
| 0 |
731 (58%) |
| 1 |
530 (42%) |
| cirrhosis |
|
| 0 |
1,207 (96%) |
| 1 |
54 (4.3%) |
| cancer_type |
|
| breast |
44 (3.5%) |
| cutaneous / melanoma |
190 (15%) |
| gi |
198 (16%) |
| gu |
246 (20%) |
| gyn |
56 (4.4%) |
| head and neck |
89 (7.1%) |
| heme |
58 (4.6%) |
| neuro |
27 (2.1%) |
| sarcoma |
9 (0.7%) |
| thoracic |
344 (27%) |
| cancer_group |
|
| cutaneous / melanoma |
190 (15%) |
| gi |
198 (16%) |
| gu |
246 (20%) |
| gyn |
56 (4.4%) |
| other |
227 (18%) |
| thoracic |
344 (27%) |
| ace_arb |
|
| 0 |
304 (24%) |
| 1 |
957 (76%) |
| diu |
|
| 0 |
352 (28%) |
| 1 |
909 (72%) |
| ppi |
|
| 0 |
239 (19%) |
| 1 |
1,022 (81%) |
| steroids |
|
| 0 |
194 (15%) |
| 1 |
1,067 (85%) |
| smoking |
|
| 0 |
482 (38%) |
| 1 |
779 (62%) |
| statins |
|
| 0 |
234 (19%) |
| 1 |
1,027 (81%) |
| ICI_Class |
|
| PD1 |
832 (66%) |
| Combination |
157 (12%) |
| CTLA4 |
44 (3.5%) |
| PDL1 |
228 (18%) |
| nephrotoxic_chemo |
|
| 0 |
604 (48%) |
| 1 |
657 (52%) |
| pre_CRE_180days |
0.95 (0.75, 1.17) |
| pre_HGB_180days |
12.20 (10.90, 13.40) |
| Missing |
5 |
| pre_ALB_180days |
4.10 (3.80, 4.30) |
| Missing |
9 |
| eGFR_CRE_baseline |
79 (61, 95) |
2year
| Characteristic |
N = 763 |
| age_ici |
69 (61, 75) |
| male |
|
| 0 |
295 (39%) |
| 1 |
468 (61%) |
| Race |
|
| Asian |
25 (3.3%) |
| Black |
47 (6.2%) |
| Other/Unknown |
39 (5.1%) |
| White |
652 (85%) |
| Ethnic_Group |
|
| Hispanic |
26 (3.4%) |
| Non_hispanic |
694 (91%) |
| Other |
43 (5.6%) |
| ckd_incidence_2year |
|
| 0 |
693 (91%) |
| 1 |
70 (9.2%) |
| ckd_progression_2year |
|
| 0 |
740 (97%) |
| 1 |
23 (3.0%) |
| eskd_composite_2year |
|
| 0 |
752 (99%) |
| 1 |
11 (1.4%) |
| ckd_composite_2year |
|
| 0 |
665 (87%) |
| 1 |
98 (13%) |
| ckd_stage_1year |
|
| 1 |
235 (31%) |
| 2 |
309 (40%) |
| 3 |
199 (26%) |
| 4 |
18 (2.4%) |
| 5 |
2 (0.3%) |
| ckd_stage_2year |
|
| 1 |
220 (29%) |
| 2 |
319 (42%) |
| 3 |
195 (26%) |
| 4 |
25 (3.3%) |
| 5 |
4 (0.5%) |
| ckd_stage_baseline |
|
| 1 |
262 (34%) |
| 2 |
315 (41%) |
| 3 |
171 (22%) |
| 4 |
14 (1.8%) |
| 5 |
1 (0.1%) |
| aki |
|
| 0 |
423 (55%) |
| 1 |
340 (45%) |
| dm |
|
| 1 |
763 (100%) |
| htn |
|
| 0 |
80 (10%) |
| 1 |
683 (90%) |
| cad |
|
| 0 |
463 (61%) |
| 1 |
300 (39%) |
| cirrhosis |
|
| 0 |
735 (96%) |
| 1 |
28 (3.7%) |
| cancer_type |
|
| breast |
30 (3.9%) |
| cutaneous / melanoma |
134 (18%) |
| gi |
94 (12%) |
| gu |
154 (20%) |
| gyn |
34 (4.5%) |
| head and neck |
52 (6.8%) |
| heme |
36 (4.7%) |
| neuro |
13 (1.7%) |
| sarcoma |
6 (0.8%) |
| thoracic |
210 (28%) |
| cancer_group |
|
| cutaneous / melanoma |
134 (18%) |
| gi |
94 (12%) |
| gu |
154 (20%) |
| gyn |
34 (4.5%) |
| other |
137 (18%) |
| thoracic |
210 (28%) |
| ace_arb |
|
| 0 |
181 (24%) |
| 1 |
582 (76%) |
| diu |
|
| 0 |
213 (28%) |
| 1 |
550 (72%) |
| ppi |
|
| 0 |
143 (19%) |
| 1 |
620 (81%) |
| steroids |
|
| 0 |
118 (15%) |
| 1 |
645 (85%) |
| smoking |
|
| 0 |
292 (38%) |
| 1 |
471 (62%) |
| statins |
|
| 0 |
142 (19%) |
| 1 |
621 (81%) |
| ICI_Class |
|
| PD1 |
510 (67%) |
| Combination |
90 (12%) |
| CTLA4 |
32 (4.2%) |
| PDL1 |
131 (17%) |
| nephrotoxic_chemo |
|
| 0 |
387 (51%) |
| 1 |
376 (49%) |
| pre_CRE_180days |
0.95 (0.76, 1.17) |
| pre_HGB_180days |
12.40 (11.00, 13.60) |
| Missing |
4 |
| pre_ALB_180days |
4.10 (3.80, 4.30) |
| Missing |
5 |
| eGFR_CRE_baseline |
80 (61, 94) |
3year
| Characteristic |
N = 446 |
| age_ici |
68 (61, 75) |
| male |
|
| 0 |
175 (39%) |
| 1 |
271 (61%) |
| Race |
|
| Asian |
16 (3.6%) |
| Black |
24 (5.4%) |
| Other/Unknown |
24 (5.4%) |
| White |
382 (86%) |
| Ethnic_Group |
|
| Hispanic |
15 (3.4%) |
| Non_hispanic |
406 (91%) |
| Other |
25 (5.6%) |
| ckd_incidence_3year |
|
| 0 |
387 (87%) |
| 1 |
59 (13%) |
| ckd_progression_3year |
|
| 0 |
427 (96%) |
| 1 |
19 (4.3%) |
| eskd_composite_3year |
|
| 0 |
440 (99%) |
| 1 |
6 (1.3%) |
| ckd_composite_3year |
|
| 0 |
365 (82%) |
| 1 |
81 (18%) |
| ckd_stage_1year |
|
| 1 |
142 (32%) |
| 2 |
175 (39%) |
| 3 |
118 (26%) |
| 4 |
10 (2.2%) |
| 5 |
1 (0.2%) |
| ckd_stage_2year |
|
| 1 |
134 (30%) |
| 2 |
187 (42%) |
| 3 |
114 (26%) |
| 4 |
11 (2.5%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
126 (28%) |
| 2 |
182 (41%) |
| 3 |
124 (28%) |
| 4 |
12 (2.7%) |
| 5 |
2 (0.4%) |
| ckd_stage_baseline |
|
| 1 |
165 (37%) |
| 2 |
176 (39%) |
| 3 |
99 (22%) |
| 4 |
6 (1.3%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
252 (57%) |
| 1 |
194 (43%) |
| dm |
|
| 1 |
446 (100%) |
| htn |
|
| 0 |
52 (12%) |
| 1 |
394 (88%) |
| cad |
|
| 0 |
272 (61%) |
| 1 |
174 (39%) |
| cirrhosis |
|
| 0 |
430 (96%) |
| 1 |
16 (3.6%) |
| cancer_type |
|
| breast |
17 (3.8%) |
| cutaneous / melanoma |
100 (22%) |
| gi |
35 (7.8%) |
| gu |
97 (22%) |
| gyn |
18 (4.0%) |
| head and neck |
31 (7.0%) |
| heme |
23 (5.2%) |
| neuro |
6 (1.3%) |
| sarcoma |
4 (0.9%) |
| thoracic |
115 (26%) |
| cancer_group |
|
| cutaneous / melanoma |
100 (22%) |
| gi |
35 (7.8%) |
| gu |
97 (22%) |
| gyn |
18 (4.0%) |
| other |
81 (18%) |
| thoracic |
115 (26%) |
| ace_arb |
|
| 0 |
98 (22%) |
| 1 |
348 (78%) |
| diu |
|
| 0 |
129 (29%) |
| 1 |
317 (71%) |
| ppi |
|
| 0 |
84 (19%) |
| 1 |
362 (81%) |
| steroids |
|
| 0 |
69 (15%) |
| 1 |
377 (85%) |
| smoking |
|
| 0 |
168 (38%) |
| 1 |
278 (62%) |
| statins |
|
| 0 |
75 (17%) |
| 1 |
371 (83%) |
| ICI_Class |
|
| PD1 |
304 (68%) |
| Combination |
51 (11%) |
| CTLA4 |
23 (5.2%) |
| PDL1 |
68 (15%) |
| nephrotoxic_chemo |
|
| 0 |
246 (55%) |
| 1 |
200 (45%) |
| pre_CRE_180days |
0.94 (0.76, 1.17) |
| pre_HGB_180days |
12.60 (11.10, 13.70) |
| Missing |
3 |
| pre_ALB_180days |
4.10 (3.80, 4.30) |
| Missing |
3 |
| eGFR_CRE_baseline |
80 (62, 96) |
4year
| Characteristic |
N = 281 |
| age_ici |
68 (60, 74) |
| male |
|
| 0 |
110 (39%) |
| 1 |
171 (61%) |
| Race |
|
| Asian |
7 (2.5%) |
| Black |
11 (3.9%) |
| Other/Unknown |
17 (6.0%) |
| White |
246 (88%) |
| Ethnic_Group |
|
| Hispanic |
11 (3.9%) |
| Non_hispanic |
251 (89%) |
| Other |
19 (6.8%) |
| ckd_incidence_4year |
|
| 0 |
238 (85%) |
| 1 |
43 (15%) |
| ckd_progression_4year |
|
| 0 |
263 (94%) |
| 1 |
18 (6.4%) |
| eskd_composite_4year |
|
| 0 |
276 (98%) |
| 1 |
5 (1.8%) |
| ckd_composite_4year |
|
| 0 |
218 (78%) |
| 1 |
63 (22%) |
| ckd_stage_1year |
|
| 1 |
86 (31%) |
| 2 |
112 (40%) |
| 3 |
73 (26%) |
| 4 |
9 (3.2%) |
| 5 |
1 (0.4%) |
| ckd_stage_2year |
|
| 1 |
81 (29%) |
| 2 |
120 (43%) |
| 3 |
71 (25%) |
| 4 |
9 (3.2%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
73 (26%) |
| 2 |
119 (42%) |
| 3 |
82 (29%) |
| 4 |
6 (2.1%) |
| 5 |
1 (0.4%) |
| ckd_stage_4year |
|
| 1 |
78 (28%) |
| 2 |
115 (41%) |
| 3 |
82 (29%) |
| 4 |
5 (1.8%) |
| 5 |
1 (0.4%) |
| ckd_stage_baseline |
|
| 1 |
96 (34%) |
| 2 |
116 (41%) |
| 3 |
65 (23%) |
| 4 |
4 (1.4%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
152 (54%) |
| 1 |
129 (46%) |
| dm |
|
| 1 |
281 (100%) |
| htn |
|
| 0 |
32 (11%) |
| 1 |
249 (89%) |
| cad |
|
| 0 |
167 (59%) |
| 1 |
114 (41%) |
| cirrhosis |
|
| 0 |
268 (95%) |
| 1 |
13 (4.6%) |
| cancer_type |
|
| breast |
8 (2.8%) |
| cutaneous / melanoma |
74 (26%) |
| gi |
18 (6.4%) |
| gu |
65 (23%) |
| gyn |
10 (3.6%) |
| head and neck |
16 (5.7%) |
| heme |
16 (5.7%) |
| neuro |
4 (1.4%) |
| sarcoma |
2 (0.7%) |
| thoracic |
68 (24%) |
| cancer_group |
|
| cutaneous / melanoma |
74 (26%) |
| gi |
18 (6.4%) |
| gu |
65 (23%) |
| gyn |
10 (3.6%) |
| other |
46 (16%) |
| thoracic |
68 (24%) |
| ace_arb |
|
| 0 |
51 (18%) |
| 1 |
230 (82%) |
| diu |
|
| 0 |
72 (26%) |
| 1 |
209 (74%) |
| ppi |
|
| 0 |
56 (20%) |
| 1 |
225 (80%) |
| steroids |
|
| 0 |
49 (17%) |
| 1 |
232 (83%) |
| smoking |
|
| 0 |
105 (37%) |
| 1 |
176 (63%) |
| statins |
|
| 0 |
40 (14%) |
| 1 |
241 (86%) |
| ICI_Class |
|
| PD1 |
194 (69%) |
| Combination |
32 (11%) |
| CTLA4 |
12 (4.3%) |
| PDL1 |
43 (15%) |
| nephrotoxic_chemo |
|
| 0 |
166 (59%) |
| 1 |
115 (41%) |
| pre_CRE_180days |
0.96 (0.78, 1.19) |
| pre_HGB_180days |
12.60 (11.10, 13.90) |
| Missing |
1 |
| pre_ALB_180days |
4.10 (3.80, 4.40) |
| Missing |
1 |
| eGFR_CRE_baseline |
79 (61, 95) |
5year
| Characteristic |
N = 177 |
| age_ici |
67 (59, 74) |
| male |
|
| 0 |
70 (40%) |
| 1 |
107 (60%) |
| Race |
|
| Asian |
3 (1.7%) |
| Black |
10 (5.6%) |
| Other/Unknown |
13 (7.3%) |
| White |
151 (85%) |
| Ethnic_Group |
|
| Hispanic |
8 (4.5%) |
| Non_hispanic |
155 (88%) |
| Other |
14 (7.9%) |
| ckd_incidence_5year |
|
| 0 |
148 (84%) |
| 1 |
29 (16%) |
| ckd_progression_5year |
|
| 0 |
160 (90%) |
| 1 |
17 (9.6%) |
| eskd_composite_5year |
|
| 0 |
174 (98%) |
| 1 |
3 (1.7%) |
| ckd_composite_5year |
|
| 0 |
129 (73%) |
| 1 |
48 (27%) |
| ckd_stage_1year |
|
| 1 |
53 (30%) |
| 2 |
75 (42%) |
| 3 |
45 (25%) |
| 4 |
4 (2.3%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
50 (28%) |
| 2 |
81 (46%) |
| 3 |
42 (24%) |
| 4 |
4 (2.3%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
46 (26%) |
| 2 |
84 (47%) |
| 3 |
45 (25%) |
| 4 |
1 (0.6%) |
| 5 |
1 (0.6%) |
| ckd_stage_4year |
|
| 1 |
50 (28%) |
| 2 |
78 (44%) |
| 3 |
47 (27%) |
| 4 |
1 (0.6%) |
| 5 |
1 (0.6%) |
| ckd_stage_5year |
|
| 1 |
44 (25%) |
| 2 |
87 (49%) |
| 3 |
40 (23%) |
| 4 |
5 (2.8%) |
| 5 |
1 (0.6%) |
| ckd_stage_baseline |
|
| 1 |
60 (34%) |
| 2 |
76 (43%) |
| 3 |
38 (21%) |
| 4 |
3 (1.7%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
104 (59%) |
| 1 |
73 (41%) |
| dm |
|
| 1 |
177 (100%) |
| htn |
|
| 0 |
20 (11%) |
| 1 |
157 (89%) |
| cad |
|
| 0 |
109 (62%) |
| 1 |
68 (38%) |
| cirrhosis |
|
| 0 |
172 (97%) |
| 1 |
5 (2.8%) |
| cancer_type |
|
| breast |
4 (2.3%) |
| cutaneous / melanoma |
52 (29%) |
| gi |
8 (4.5%) |
| gu |
34 (19%) |
| gyn |
7 (4.0%) |
| head and neck |
12 (6.8%) |
| heme |
13 (7.3%) |
| neuro |
2 (1.1%) |
| sarcoma |
2 (1.1%) |
| thoracic |
43 (24%) |
| cancer_group |
|
| cutaneous / melanoma |
52 (29%) |
| gi |
8 (4.5%) |
| gu |
34 (19%) |
| gyn |
7 (4.0%) |
| other |
33 (19%) |
| thoracic |
43 (24%) |
| ace_arb |
|
| 0 |
35 (20%) |
| 1 |
142 (80%) |
| diu |
|
| 0 |
43 (24%) |
| 1 |
134 (76%) |
| ppi |
|
| 0 |
35 (20%) |
| 1 |
142 (80%) |
| steroids |
|
| 0 |
34 (19%) |
| 1 |
143 (81%) |
| smoking |
|
| 0 |
68 (38%) |
| 1 |
109 (62%) |
| statins |
|
| 0 |
23 (13%) |
| 1 |
154 (87%) |
| ICI_Class |
|
| PD1 |
124 (70%) |
| Combination |
14 (7.9%) |
| CTLA4 |
9 (5.1%) |
| PDL1 |
30 (17%) |
| nephrotoxic_chemo |
|
| 0 |
108 (61%) |
| 1 |
69 (39%) |
| pre_CRE_180days |
0.95 (0.75, 1.16) |
| pre_HGB_180days |
12.60 (11.15, 13.85) |
| Missing |
1 |
| pre_ALB_180days |
4.10 (3.80, 4.30) |
| Missing |
1 |
| eGFR_CRE_baseline |
79 (61, 96) |
6year
| Characteristic |
N = 114 |
| age_ici |
65 (59, 74) |
| male |
|
| 0 |
47 (41%) |
| 1 |
67 (59%) |
| Race |
|
| Asian |
2 (1.8%) |
| Black |
9 (7.9%) |
| Other/Unknown |
10 (8.8%) |
| White |
93 (82%) |
| Ethnic_Group |
|
| Hispanic |
5 (4.4%) |
| Non_hispanic |
98 (86%) |
| Other |
11 (9.6%) |
| ckd_incidence_6year |
|
| 0 |
93 (82%) |
| 1 |
21 (18%) |
| ckd_progression_6year |
|
| 0 |
103 (90%) |
| 1 |
11 (9.6%) |
| eskd_composite_6year |
|
| 0 |
112 (98%) |
| 1 |
2 (1.8%) |
| ckd_composite_6year |
34 (30%) |
| ckd_stage_1year |
|
| 1 |
38 (33%) |
| 2 |
49 (43%) |
| 3 |
26 (23%) |
| 4 |
1 (0.9%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
35 (31%) |
| 2 |
53 (46%) |
| 3 |
26 (23%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
35 (31%) |
| 2 |
50 (44%) |
| 3 |
28 (25%) |
| 4 |
1 (0.9%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
36 (32%) |
| 2 |
49 (43%) |
| 3 |
29 (25%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
31 (27%) |
| 2 |
56 (49%) |
| 3 |
25 (22%) |
| 4 |
2 (1.8%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
30 (26%) |
| 2 |
56 (49%) |
| 3 |
22 (19%) |
| 4 |
6 (5.3%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
43 (38%) |
| 2 |
46 (40%) |
| 3 |
24 (21%) |
| 4 |
1 (0.9%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
67 (59%) |
| 1 |
47 (41%) |
| dm |
|
| 1 |
114 (100%) |
| htn |
|
| 0 |
14 (12%) |
| 1 |
100 (88%) |
| cad |
|
| 0 |
75 (66%) |
| 1 |
39 (34%) |
| cirrhosis |
|
| 0 |
112 (98%) |
| 1 |
2 (1.8%) |
| cancer_type |
|
| breast |
3 (2.6%) |
| cutaneous / melanoma |
38 (33%) |
| gi |
4 (3.5%) |
| gu |
18 (16%) |
| gyn |
3 (2.6%) |
| head and neck |
9 (7.9%) |
| heme |
10 (8.8%) |
| neuro |
1 (0.9%) |
| sarcoma |
1 (0.9%) |
| thoracic |
27 (24%) |
| cancer_group |
|
| cutaneous / melanoma |
38 (33%) |
| gi |
4 (3.5%) |
| gu |
18 (16%) |
| gyn |
3 (2.6%) |
| other |
24 (21%) |
| thoracic |
27 (24%) |
| ace_arb |
|
| 0 |
24 (21%) |
| 1 |
90 (79%) |
| diu |
|
| 0 |
30 (26%) |
| 1 |
84 (74%) |
| ppi |
|
| 0 |
23 (20%) |
| 1 |
91 (80%) |
| steroids |
|
| 0 |
22 (19%) |
| 1 |
92 (81%) |
| smoking |
|
| 0 |
48 (42%) |
| 1 |
66 (58%) |
| statins |
|
| 0 |
13 (11%) |
| 1 |
101 (89%) |
| ICI_Class |
|
| PD1 |
75 (66%) |
| Combination |
8 (7.0%) |
| CTLA4 |
8 (7.0%) |
| PDL1 |
23 (20%) |
| nephrotoxic_chemo |
|
| 0 |
73 (64%) |
| 1 |
41 (36%) |
| pre_CRE_180days |
0.93 (0.72, 1.12) |
| pre_HGB_180days |
12.60 (11.10, 13.90) |
| pre_ALB_180days |
4.10 (3.80, 4.30) |
| eGFR_CRE_baseline |
82 (66, 98) |
7year
| Characteristic |
N = 76 |
| age_ici |
64 (58, 73) |
| male |
|
| 0 |
28 (37%) |
| 1 |
48 (63%) |
| Race |
|
| Asian |
1 (1.3%) |
| Black |
6 (7.9%) |
| Other/Unknown |
7 (9.2%) |
| White |
62 (82%) |
| Ethnic_Group |
|
| Hispanic |
4 (5.3%) |
| Non_hispanic |
64 (84%) |
| Other |
8 (11%) |
| ckd_incidence_7year |
|
| 0 |
56 (74%) |
| 1 |
20 (26%) |
| ckd_progression_7year |
|
| 0 |
72 (95%) |
| 1 |
4 (5.3%) |
| eskd_composite_7year |
|
| 0 |
75 (99%) |
| 1 |
1 (1.3%) |
| ckd_composite_7year |
25 (33%) |
| ckd_stage_1year |
|
| 1 |
28 (37%) |
| 2 |
32 (42%) |
| 3 |
15 (20%) |
| 4 |
1 (1.3%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
25 (33%) |
| 2 |
34 (45%) |
| 3 |
17 (22%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
24 (32%) |
| 2 |
35 (46%) |
| 3 |
17 (22%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
25 (33%) |
| 2 |
31 (41%) |
| 3 |
20 (26%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
20 (26%) |
| 2 |
39 (51%) |
| 3 |
16 (21%) |
| 4 |
1 (1.3%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
20 (26%) |
| 2 |
37 (49%) |
| 3 |
15 (20%) |
| 4 |
4 (5.3%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
20 (26%) |
| 2 |
33 (43%) |
| 3 |
19 (25%) |
| 4 |
3 (3.9%) |
| 5 |
1 (1.3%) |
| ckd_stage_baseline |
|
| 1 |
30 (39%) |
| 2 |
30 (39%) |
| 3 |
15 (20%) |
| 4 |
1 (1.3%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
47 (62%) |
| 1 |
29 (38%) |
| dm |
|
| 1 |
76 (100%) |
| htn |
|
| 0 |
10 (13%) |
| 1 |
66 (87%) |
| cad |
|
| 0 |
53 (70%) |
| 1 |
23 (30%) |
| cirrhosis |
|
| 0 |
74 (97%) |
| 1 |
2 (2.6%) |
| cancer_type |
|
| breast |
0 (0%) |
| cutaneous / melanoma |
29 (38%) |
| gi |
1 (1.3%) |
| gu |
12 (16%) |
| gyn |
2 (2.6%) |
| head and neck |
6 (7.9%) |
| heme |
7 (9.2%) |
| neuro |
1 (1.3%) |
| sarcoma |
1 (1.3%) |
| thoracic |
17 (22%) |
| cancer_group |
|
| cutaneous / melanoma |
29 (38%) |
| gi |
1 (1.3%) |
| gu |
12 (16%) |
| gyn |
2 (2.6%) |
| other |
15 (20%) |
| thoracic |
17 (22%) |
| ace_arb |
|
| 0 |
15 (20%) |
| 1 |
61 (80%) |
| diu |
|
| 0 |
24 (32%) |
| 1 |
52 (68%) |
| ppi |
|
| 0 |
15 (20%) |
| 1 |
61 (80%) |
| steroids |
|
| 0 |
14 (18%) |
| 1 |
62 (82%) |
| smoking |
|
| 0 |
29 (38%) |
| 1 |
47 (62%) |
| statins |
|
| 0 |
5 (6.6%) |
| 1 |
71 (93%) |
| ICI_Class |
|
| PD1 |
53 (70%) |
| Combination |
4 (5.3%) |
| CTLA4 |
6 (7.9%) |
| PDL1 |
13 (17%) |
| nephrotoxic_chemo |
|
| 0 |
50 (66%) |
| 1 |
26 (34%) |
| pre_CRE_180days |
0.95 (0.76, 1.11) |
| pre_HGB_180days |
12.60 (11.00, 13.90) |
| pre_ALB_180days |
4.10 (3.90, 4.30) |
| eGFR_CRE_baseline |
82 (69, 98) |
8year
| Characteristic |
N = 40 |
| age_ici |
67 (58, 73) |
| male |
|
| 0 |
12 (30%) |
| 1 |
28 (70%) |
| Race |
|
| Asian |
0 (0%) |
| Black |
3 (7.5%) |
| Other/Unknown |
2 (5.0%) |
| White |
35 (88%) |
| Ethnic_Group |
|
| Hispanic |
1 (2.5%) |
| Non_hispanic |
34 (85%) |
| Other |
5 (13%) |
| ckd_incidence_8year |
|
| 0 |
26 (65%) |
| 1 |
14 (35%) |
| ckd_progression_8year |
|
| 0 |
36 (90%) |
| 1 |
4 (10%) |
| eskd_composite_8year |
|
| 0 |
40 (100%) |
| 1 |
0 (0%) |
| ckd_composite_8year |
18 (45%) |
| ckd_stage_1year |
|
| 1 |
13 (33%) |
| 2 |
18 (45%) |
| 3 |
9 (23%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
9 (23%) |
| 2 |
21 (53%) |
| 3 |
10 (25%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
11 (28%) |
| 2 |
19 (48%) |
| 3 |
10 (25%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
13 (33%) |
| 2 |
14 (35%) |
| 3 |
13 (33%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
9 (23%) |
| 2 |
19 (48%) |
| 3 |
12 (30%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
8 (20%) |
| 2 |
20 (50%) |
| 3 |
11 (28%) |
| 4 |
1 (2.5%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
9 (23%) |
| 2 |
14 (35%) |
| 3 |
15 (38%) |
| 4 |
2 (5.0%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
8 (20%) |
| 2 |
14 (35%) |
| 3 |
16 (40%) |
| 4 |
2 (5.0%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
12 (30%) |
| 2 |
17 (43%) |
| 3 |
11 (28%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
22 (55%) |
| 1 |
18 (45%) |
| dm |
|
| 1 |
40 (100%) |
| htn |
|
| 0 |
2 (5.0%) |
| 1 |
38 (95%) |
| cad |
|
| 0 |
26 (65%) |
| 1 |
14 (35%) |
| cirrhosis |
|
| 0 |
38 (95%) |
| 1 |
2 (5.0%) |
| cancer_type |
|
| breast |
0 (0%) |
| cutaneous / melanoma |
20 (50%) |
| gi |
0 (0%) |
| gu |
7 (18%) |
| gyn |
0 (0%) |
| head and neck |
1 (2.5%) |
| heme |
3 (7.5%) |
| neuro |
1 (2.5%) |
| sarcoma |
0 (0%) |
| thoracic |
8 (20%) |
| cancer_group |
|
| cutaneous / melanoma |
20 (50%) |
| gi |
0 (0%) |
| gu |
7 (18%) |
| gyn |
0 (0%) |
| other |
5 (13%) |
| thoracic |
8 (20%) |
| ace_arb |
|
| 0 |
8 (20%) |
| 1 |
32 (80%) |
| diu |
|
| 0 |
11 (28%) |
| 1 |
29 (73%) |
| ppi |
|
| 0 |
9 (23%) |
| 1 |
31 (78%) |
| steroids |
|
| 0 |
10 (25%) |
| 1 |
30 (75%) |
| smoking |
|
| 0 |
15 (38%) |
| 1 |
25 (63%) |
| statins |
|
| 0 |
2 (5.0%) |
| 1 |
38 (95%) |
| ICI_Class |
|
| PD1 |
26 (65%) |
| Combination |
2 (5.0%) |
| CTLA4 |
5 (13%) |
| PDL1 |
7 (18%) |
| nephrotoxic_chemo |
|
| 0 |
30 (75%) |
| 1 |
10 (25%) |
| pre_CRE_180days |
1.02 (0.78, 1.24) |
| pre_HGB_180days |
12.55 (10.95, 13.95) |
| pre_ALB_180days |
4.10 (3.90, 4.30) |
| eGFR_CRE_baseline |
79 (59, 95) |
9year
| Characteristic |
N = 17 |
| age_ici |
67 (57, 74) |
| male |
|
| 0 |
6 (35%) |
| 1 |
11 (65%) |
| Race |
|
| Asian |
0 (0%) |
| Black |
0 (0%) |
| Other/Unknown |
0 (0%) |
| White |
17 (100%) |
| Ethnic_Group |
|
| Hispanic |
0 (0%) |
| Non_hispanic |
16 (94%) |
| Other |
1 (5.9%) |
| ckd_incidence_9year |
|
| 0 |
12 (71%) |
| 1 |
5 (29%) |
| ckd_progression_9year |
|
| 0 |
15 (88%) |
| 1 |
2 (12%) |
| eskd_composite_9year |
|
| 0 |
17 (100%) |
| 1 |
0 (0%) |
| ckd_composite_9year |
7 (41%) |
| ckd_stage_1year |
|
| 1 |
4 (24%) |
| 2 |
10 (59%) |
| 3 |
3 (18%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
3 (18%) |
| 2 |
10 (59%) |
| 3 |
4 (24%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
4 (24%) |
| 2 |
9 (53%) |
| 3 |
4 (24%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
7 (41%) |
| 2 |
5 (29%) |
| 3 |
5 (29%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
4 (24%) |
| 2 |
8 (47%) |
| 3 |
5 (29%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
4 (24%) |
| 2 |
7 (41%) |
| 3 |
6 (35%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
6 (35%) |
| 2 |
5 (29%) |
| 3 |
6 (35%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
5 (29%) |
| 2 |
6 (35%) |
| 3 |
5 (29%) |
| 4 |
1 (5.9%) |
| 5 |
0 (0%) |
| ckd_stage_9year |
|
| 1 |
7 (41%) |
| 2 |
3 (18%) |
| 3 |
7 (41%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
4 (24%) |
| 2 |
9 (53%) |
| 3 |
4 (24%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
8 (47%) |
| 1 |
9 (53%) |
| dm |
|
| 1 |
17 (100%) |
| htn |
|
| 0 |
0 (0%) |
| 1 |
17 (100%) |
| cad |
|
| 0 |
12 (71%) |
| 1 |
5 (29%) |
| cirrhosis |
|
| 0 |
17 (100%) |
| 1 |
0 (0%) |
| cancer_type |
|
| breast |
0 (0%) |
| cutaneous / melanoma |
9 (53%) |
| gi |
0 (0%) |
| gu |
2 (12%) |
| gyn |
0 (0%) |
| head and neck |
0 (0%) |
| heme |
1 (5.9%) |
| neuro |
0 (0%) |
| sarcoma |
0 (0%) |
| thoracic |
5 (29%) |
| cancer_group |
|
| cutaneous / melanoma |
9 (53%) |
| gi |
0 (0%) |
| gu |
2 (12%) |
| gyn |
0 (0%) |
| other |
1 (5.9%) |
| thoracic |
5 (29%) |
| ace_arb |
|
| 0 |
4 (24%) |
| 1 |
13 (76%) |
| diu |
|
| 0 |
4 (24%) |
| 1 |
13 (76%) |
| ppi |
|
| 0 |
2 (12%) |
| 1 |
15 (88%) |
| steroids |
|
| 0 |
3 (18%) |
| 1 |
14 (82%) |
| smoking |
|
| 0 |
5 (29%) |
| 1 |
12 (71%) |
| statins |
|
| 0 |
0 (0%) |
| 1 |
17 (100%) |
| ICI_Class |
|
| PD1 |
9 (53%) |
| Combination |
0 (0%) |
| CTLA4 |
4 (24%) |
| PDL1 |
4 (24%) |
| nephrotoxic_chemo |
|
| 0 |
11 (65%) |
| 1 |
6 (35%) |
| pre_CRE_180days |
1.02 (0.83, 1.09) |
| pre_HGB_180days |
12.60 (11.70, 14.40) |
| pre_ALB_180days |
|
| 3.5 |
1 (5.9%) |
| 3.9 |
1 (5.9%) |
| 4 |
2 (12%) |
| 4.1 |
2 (12%) |
| 4.2 |
5 (29%) |
| 4.3 |
3 (18%) |
| 4.4 |
2 (12%) |
| 4.8 |
1 (5.9%) |
| eGFR_CRE_baseline |
77 (61, 88) |
10year
| Characteristic |
N = 6 |
| age_ici |
|
| 60 |
1 (17%) |
| 67 |
1 (17%) |
| 71 |
1 (17%) |
| 72 |
1 (17%) |
| 74 |
1 (17%) |
| 75 |
1 (17%) |
| male |
|
| 0 |
2 (33%) |
| 1 |
4 (67%) |
| Race |
|
| Asian |
0 (0%) |
| Black |
0 (0%) |
| Other/Unknown |
0 (0%) |
| White |
6 (100%) |
| Ethnic_Group |
|
| Hispanic |
0 (0%) |
| Non_hispanic |
6 (100%) |
| Other |
0 (0%) |
| ckd_incidence_10year |
|
| 0 |
3 (50%) |
| 1 |
3 (50%) |
| ckd_progression_10year |
|
| 0 |
5 (83%) |
| 1 |
1 (17%) |
| eskd_composite_10year |
|
| 0 |
5 (83%) |
| 1 |
1 (17%) |
| ckd_composite_10year |
4 (67%) |
| ckd_stage_1year |
|
| 1 |
1 (17%) |
| 2 |
3 (50%) |
| 3 |
2 (33%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
1 (17%) |
| 2 |
2 (33%) |
| 3 |
3 (50%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
1 (17%) |
| 2 |
2 (33%) |
| 3 |
3 (50%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
1 (17%) |
| 2 |
2 (33%) |
| 3 |
3 (50%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
1 (17%) |
| 2 |
2 (33%) |
| 3 |
3 (50%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
1 (17%) |
| 2 |
2 (33%) |
| 3 |
3 (50%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
0 (0%) |
| 2 |
2 (33%) |
| 3 |
4 (67%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
1 (17%) |
| 2 |
1 (17%) |
| 3 |
3 (50%) |
| 4 |
1 (17%) |
| 5 |
0 (0%) |
| ckd_stage_9year |
|
| 1 |
1 (17%) |
| 2 |
0 (0%) |
| 3 |
5 (83%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_10year |
|
| 1 |
0 (0%) |
| 2 |
1 (17%) |
| 3 |
3 (50%) |
| 4 |
2 (33%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
1 (17%) |
| 2 |
3 (50%) |
| 3 |
2 (33%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
3 (50%) |
| 1 |
3 (50%) |
| dm |
|
| 1 |
6 (100%) |
| htn |
|
| 0 |
0 (0%) |
| 1 |
6 (100%) |
| cad |
|
| 0 |
4 (67%) |
| 1 |
2 (33%) |
| cirrhosis |
|
| 0 |
6 (100%) |
| 1 |
0 (0%) |
| cancer_type |
|
| breast |
0 (0%) |
| cutaneous / melanoma |
5 (83%) |
| gi |
0 (0%) |
| gu |
0 (0%) |
| gyn |
0 (0%) |
| head and neck |
0 (0%) |
| heme |
0 (0%) |
| neuro |
0 (0%) |
| sarcoma |
0 (0%) |
| thoracic |
1 (17%) |
| cancer_group |
|
| cutaneous / melanoma |
5 (83%) |
| gi |
0 (0%) |
| gu |
0 (0%) |
| gyn |
0 (0%) |
| other |
0 (0%) |
| thoracic |
1 (17%) |
| ace_arb |
|
| 0 |
0 (0%) |
| 1 |
6 (100%) |
| diu |
|
| 0 |
1 (17%) |
| 1 |
5 (83%) |
| ppi |
|
| 0 |
0 (0%) |
| 1 |
6 (100%) |
| steroids |
|
| 0 |
1 (17%) |
| 1 |
5 (83%) |
| smoking |
|
| 0 |
0 (0%) |
| 1 |
6 (100%) |
| statins |
|
| 0 |
0 (0%) |
| 1 |
6 (100%) |
| ICI_Class |
|
| PD1 |
3 (50%) |
| Combination |
0 (0%) |
| CTLA4 |
3 (50%) |
| PDL1 |
0 (0%) |
| nephrotoxic_chemo |
|
| 0 |
4 (67%) |
| 1 |
2 (33%) |
| pre_CRE_180days |
|
| 0.66 |
1 (17%) |
| 0.81 |
1 (17%) |
| 1.01 |
1 (17%) |
| 1.02 |
1 (17%) |
| 1.3 |
1 (17%) |
| 1.52 |
1 (17%) |
| pre_HGB_180days |
|
| 11.3 |
1 (17%) |
| 12.2 |
1 (17%) |
| 13.3 |
1 (17%) |
| 13.9 |
1 (17%) |
| 14.6 |
1 (17%) |
| 14.8 |
1 (17%) |
| pre_ALB_180days |
|
| 4.1 |
1 (17%) |
| 4.2 |
1 (17%) |
| 4.3 |
2 (33%) |
| 4.4 |
1 (17%) |
| 4.8 |
1 (17%) |
| eGFR_CRE_baseline |
|
| 47.0718538399253 |
1 (17%) |
| 59.186554146736 |
1 (17%) |
| 61.3166133202947 |
1 (17%) |
| 80.4651484382125 |
1 (17%) |
| 82.827699890859 |
1 (17%) |
| 104.256040676399 |
1 (17%) |
CIF survival all Event number : death + ckd composite
ckd_stage vs ckd_composite_1year
|
0
(N=1181) |
1
(N=80) |
Overall
(N=1261) |
| ckd_stage_baseline |
|
|
|
| 1 |
424 (35.9%) |
9 (11.3%) |
433 (34.3%) |
| 2 |
465 (39.4%) |
51 (63.8%) |
516 (40.9%) |
| 3 |
274 (23.2%) |
17 (21.3%) |
291 (23.1%) |
| 4 |
18 (1.5%) |
2 (2.5%) |
20 (1.6%) |
| 5 |
0 (0%) |
1 (1.3%) |
1 (0.1%) |
| factor(ckd_stage_1year) |
|
|
|
| 1 |
393 (33.3%) |
0 (0%) |
393 (31.2%) |
| 2 |
495 (41.9%) |
9 (11.3%) |
504 (40.0%) |
| 3 |
272 (23.0%) |
57 (71.3%) |
329 (26.1%) |
| 4 |
21 (1.8%) |
11 (13.8%) |
32 (2.5%) |
| 5 |
0 (0%) |
3 (3.8%) |
3 (0.2%) |
ckd_stage vs ckd_composite_2year
|
0
(N=665) |
1
(N=98) |
Overall
(N=763) |
| ckd_stage_baseline |
|
|
|
| 1 |
249 (37.4%) |
13 (13.3%) |
262 (34.3%) |
| 2 |
256 (38.5%) |
59 (60.2%) |
315 (41.3%) |
| 3 |
149 (22.4%) |
22 (22.4%) |
171 (22.4%) |
| 4 |
11 (1.7%) |
3 (3.1%) |
14 (1.8%) |
| 5 |
0 (0%) |
1 (1.0%) |
1 (0.1%) |
| factor(ckd_stage_2year) |
|
|
|
| 1 |
220 (33.1%) |
0 (0%) |
220 (28.8%) |
| 2 |
302 (45.4%) |
17 (17.3%) |
319 (41.8%) |
| 3 |
127 (19.1%) |
68 (69.4%) |
195 (25.6%) |
| 4 |
16 (2.4%) |
9 (9.2%) |
25 (3.3%) |
| 5 |
0 (0%) |
4 (4.1%) |
4 (0.5%) |
ckd_stage vs ckd_composite_3year
|
0
(N=365) |
1
(N=81) |
Overall
(N=446) |
| ckd_stage_baseline |
|
|
|
| 1 |
151 (41.4%) |
14 (17.3%) |
165 (37.0%) |
| 2 |
130 (35.6%) |
46 (56.8%) |
176 (39.5%) |
| 3 |
80 (21.9%) |
19 (23.5%) |
99 (22.2%) |
| 4 |
4 (1.1%) |
2 (2.5%) |
6 (1.3%) |
| 5 |
0 (0%) |
0 (0%) |
0 (0%) |
| factor(ckd_stage_3year) |
|
|
|
| 1 |
124 (34.0%) |
2 (2.5%) |
126 (28.3%) |
| 2 |
160 (43.8%) |
22 (27.2%) |
182 (40.8%) |
| 3 |
76 (20.8%) |
48 (59.3%) |
124 (27.8%) |
| 4 |
5 (1.4%) |
7 (8.6%) |
12 (2.7%) |
| 5 |
0 (0%) |
2 (2.5%) |
2 (0.4%) |
ckd_stage vs ckd_composite_4year
|
0
(N=218) |
1
(N=63) |
Overall
(N=281) |
| ckd_stage_baseline |
|
|
|
| 1 |
85 (39.0%) |
11 (17.5%) |
96 (34.2%) |
| 2 |
83 (38.1%) |
33 (52.4%) |
116 (41.3%) |
| 3 |
47 (21.6%) |
18 (28.6%) |
65 (23.1%) |
| 4 |
3 (1.4%) |
1 (1.6%) |
4 (1.4%) |
| 5 |
0 (0%) |
0 (0%) |
0 (0%) |
| factor(ckd_stage_4year) |
|
|
|
| 1 |
77 (35.3%) |
1 (1.6%) |
78 (27.8%) |
| 2 |
94 (43.1%) |
21 (33.3%) |
115 (40.9%) |
| 3 |
45 (20.6%) |
37 (58.7%) |
82 (29.2%) |
| 4 |
2 (0.9%) |
3 (4.8%) |
5 (1.8%) |
| 5 |
0 (0%) |
1 (1.6%) |
1 (0.4%) |
ckd_stage vs ckd_composite_5year
|
0
(N=129) |
1
(N=48) |
Overall
(N=177) |
| ckd_stage_baseline |
|
|
|
| 1 |
57 (44.2%) |
3 (6.3%) |
60 (33.9%) |
| 2 |
49 (38.0%) |
27 (56.3%) |
76 (42.9%) |
| 3 |
21 (16.3%) |
17 (35.4%) |
38 (21.5%) |
| 4 |
2 (1.6%) |
1 (2.1%) |
3 (1.7%) |
| 5 |
0 (0%) |
0 (0%) |
0 (0%) |
| factor(ckd_stage_5year) |
|
|
|
| 1 |
40 (31.0%) |
4 (8.3%) |
44 (24.9%) |
| 2 |
74 (57.4%) |
13 (27.1%) |
87 (49.2%) |
| 3 |
12 (9.3%) |
28 (58.3%) |
40 (22.6%) |
| 4 |
3 (2.3%) |
2 (4.2%) |
5 (2.8%) |
| 5 |
0 (0%) |
1 (2.1%) |
1 (0.6%) |
Table 5 year aki
|
Overall
(N=48) |
| aki |
|
| 0 |
17 (35.4%) |
| 1 |
31 (64.6%) |
| as.factor(aki_before_ckd) |
|
| 0 |
9 (18.8%) |
| 1 |
22 (45.8%) |
| Missing |
17 (35.4%) |
|
Overall
(N=2653) |
| aki |
|
| 0 |
1651 (62.2%) |
| 1 |
1002 (37.8%) |
| as.factor(aki_before_ckd) |
|
| 0 |
46 (1.7%) |
| 1 |
104 (3.9%) |
| Missing |
2503 (94.3%) |
| ckd_composite |
|
| 0 |
2420 (91.2%) |
| 1 |
233 (8.8%) |
Table ckd_composite==1 columns:aki_before_ckd
| Characteristic |
N = 207 |
| age_ici |
71 (64, 77) |
| male |
|
| 0 |
93 (45%) |
| 1 |
114 (55%) |
| Race |
|
| Asian |
3 (1.4%) |
| Black |
13 (6.3%) |
| Other/Unknown |
9 (4.3%) |
| White |
182 (88%) |
| Ethnic_Group |
|
| Hispanic |
8 (3.9%) |
| Non_hispanic |
186 (90%) |
| Other |
13 (6.3%) |
| ckd_incidence_1year |
|
| 0 |
148 (71%) |
| 1 |
59 (29%) |
| ckd_progression_1year |
|
| 0 |
190 (92%) |
| 1 |
17 (8.2%) |
| eskd_composite_1year |
|
| 0 |
199 (96%) |
| 1 |
8 (3.9%) |
| ckd_composite_1year |
|
| 0 |
127 (61%) |
| 1 |
80 (39%) |
| ckd_stage_1year |
|
| 1 |
14 (6.8%) |
| 2 |
66 (32%) |
| 3 |
108 (52%) |
| 4 |
16 (7.7%) |
| 5 |
3 (1.4%) |
| ckd_stage_baseline |
|
| 1 |
32 (15%) |
| 2 |
115 (56%) |
| 3 |
52 (25%) |
| 4 |
7 (3.4%) |
| 5 |
1 (0.5%) |
| aki |
|
| 0 |
76 (37%) |
| 1 |
131 (63%) |
| dm |
|
| 1 |
207 (100%) |
| htn |
|
| 0 |
19 (9.2%) |
| 1 |
188 (91%) |
| cad |
|
| 0 |
98 (47%) |
| 1 |
109 (53%) |
| cirrhosis |
|
| 0 |
201 (97%) |
| 1 |
6 (2.9%) |
| cancer_type |
|
| breast |
3 (1.4%) |
| cutaneous / melanoma |
35 (17%) |
| gi |
30 (14%) |
| gu |
52 (25%) |
| gyn |
10 (4.8%) |
| head and neck |
9 (4.3%) |
| heme |
10 (4.8%) |
| neuro |
1 (0.5%) |
| sarcoma |
0 (0%) |
| thoracic |
57 (28%) |
| cancer_group |
|
| cutaneous / melanoma |
35 (17%) |
| gi |
30 (14%) |
| gu |
52 (25%) |
| gyn |
10 (4.8%) |
| other |
23 (11%) |
| thoracic |
57 (28%) |
| ace_arb |
|
| 0 |
42 (20%) |
| 1 |
165 (80%) |
| diu |
|
| 0 |
42 (20%) |
| 1 |
165 (80%) |
| ppi |
|
| 0 |
34 (16%) |
| 1 |
173 (84%) |
| steroids |
|
| 0 |
40 (19%) |
| 1 |
167 (81%) |
| smoking |
|
| 0 |
77 (37%) |
| 1 |
130 (63%) |
| statins |
|
| 0 |
25 (12%) |
| 1 |
182 (88%) |
| ICI_Class |
|
| PD1 |
136 (66%) |
| Combination |
31 (15%) |
| CTLA4 |
6 (2.9%) |
| PDL1 |
34 (16%) |
| nephrotoxic_chemo |
|
| 0 |
114 (55%) |
| 1 |
93 (45%) |
| pre_CRE_180days |
1.01 (0.82, 1.23) |
| pre_HGB_180days |
11.90 (10.80, 13.10) |
| Missing |
1 |
| pre_ALB_180days |
4.00 (3.70, 4.20) |
| Missing |
3 |
| eGFR_CRE_baseline |
74 (55, 83) |
| Characteristic |
0
N = 129 |
1
N = 104 |
| age_ici |
71 (66, 78) |
71 (63, 78) |
| male |
|
|
| 0 |
58 (45%) |
48 (46%) |
| 1 |
71 (55%) |
56 (54%) |
| Race |
|
|
| Asian |
2 (1.6%) |
1 (1.0%) |
| Black |
7 (5.4%) |
7 (6.7%) |
| Other/Unknown |
5 (3.9%) |
5 (4.8%) |
| White |
115 (89%) |
91 (88%) |
| Ethnic_Group |
|
|
| Hispanic |
6 (4.7%) |
5 (4.8%) |
| Non_hispanic |
117 (91%) |
92 (88%) |
| Other |
6 (4.7%) |
7 (6.7%) |
| ckd_composite |
|
|
| 0 |
0 (0%) |
0 (0%) |
| 1 |
129 (100%) |
104 (100%) |
| ckd_incidence |
|
|
| 0 |
31 (24%) |
48 (46%) |
| 1 |
98 (76%) |
56 (54%) |
| ckd_progression |
|
|
| 0 |
108 (84%) |
69 (66%) |
| 1 |
21 (16%) |
35 (34%) |
| ckd_stage_baseline |
|
|
| 1 |
12 (9.3%) |
21 (20%) |
| 2 |
88 (68%) |
40 (38%) |
| 3 |
22 (17%) |
38 (37%) |
| 4 |
5 (3.9%) |
4 (3.8%) |
| 5 |
2 (1.6%) |
1 (1.0%) |
| aki |
|
|
| 0 |
83 (64%) |
0 (0%) |
| 1 |
46 (36%) |
104 (100%) |
| dm |
|
|
| 1 |
129 (100%) |
104 (100%) |
| htn |
|
|
| 0 |
16 (12%) |
6 (5.8%) |
| 1 |
113 (88%) |
98 (94%) |
| cad |
|
|
| 0 |
70 (54%) |
44 (42%) |
| 1 |
59 (46%) |
60 (58%) |
| cirrhosis |
|
|
| 0 |
126 (98%) |
99 (95%) |
| 1 |
3 (2.3%) |
5 (4.8%) |
| ace_arb |
|
|
| 0 |
32 (25%) |
14 (13%) |
| 1 |
97 (75%) |
90 (87%) |
| diu |
|
|
| 0 |
36 (28%) |
12 (12%) |
| 1 |
93 (72%) |
92 (88%) |
| ppi |
|
|
| 0 |
25 (19%) |
16 (15%) |
| 1 |
104 (81%) |
88 (85%) |
| steroids |
|
|
| 0 |
25 (19%) |
18 (17%) |
| 1 |
104 (81%) |
86 (83%) |
| smoking |
|
|
| 0 |
53 (41%) |
33 (32%) |
| 1 |
76 (59%) |
71 (68%) |
| statins |
|
|
| 0 |
20 (16%) |
7 (6.7%) |
| 1 |
109 (84%) |
97 (93%) |
| ICI_Class |
|
|
| PD1 |
90 (70%) |
65 (63%) |
| Combination |
18 (14%) |
15 (14%) |
| CTLA4 |
3 (2.3%) |
3 (2.9%) |
| PDL1 |
18 (14%) |
21 (20%) |
| nephrotoxic_chemo |
|
|
| 0 |
67 (52%) |
59 (57%) |
| 1 |
62 (48%) |
45 (43%) |
| pre_CRE_180days |
0.99 (0.81, 1.20) |
1.05 (0.83, 1.39) |
| pre_HGB_180days |
11.80 (10.45, 13.10) |
11.80 (10.70, 12.75) |
| Missing |
1 |
0 |
| pre_ALB_180days |
4.00 (3.60, 4.20) |
3.90 (3.70, 4.15) |
| Missing |
3 |
0 |
| eGFR_CRE_baseline |
75 (63, 82) |
68 (50, 84) |
logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
177 |
1.50 |
1.07, 2.16 |
0.024 |
| male |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.49 |
0.25, 0.96 |
0.039 |
| Race |
177 |
|
|
|
| Asian |
|
— |
— |
|
| Black |
|
3,838,542 |
0.00,
|
0.986 |
| Other/Unknown |
|
2,559,028 |
0.00,
|
0.986 |
| White |
|
2,074,887 |
0.00,
|
0.986 |
| htn |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.28 |
0.72, 10.1 |
0.206 |
| cad |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
3.12 |
1.58, 6.25 |
0.001 |
| cirrhosis |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.66 |
0.03, 4.64 |
0.718 |
| ace_arb |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.03 |
0.83, 5.73 |
0.144 |
| diu |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
3.59 |
1.43, 11.0 |
0.012 |
| ppi |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.32 |
0.57, 3.34 |
0.528 |
| steroids |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.73 |
0.33, 1.69 |
0.446 |
| smoking |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.19 |
0.60, 2.41 |
0.617 |
| statins |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.90 |
0.67, 6.83 |
0.267 |
| nephrotoxic_chemo |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.92 |
0.46, 1.80 |
0.805 |
| Bevacizumab |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.84 |
0.65, 12.5 |
0.152 |
| Cisplatin |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.55 |
0.12, 1.78 |
0.362 |
| Carboplatin |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.22 |
0.58, 2.49 |
0.589 |
| Pemetrexed |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.30 |
0.47, 3.31 |
0.597 |
| Gemcitabine |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.66 |
0.59, 4.43 |
0.317 |
| Cetuximab |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.989 |
| Trastuzumab |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.989 |
| eGFR_CRE_baseline_decrease_10 |
177 |
1.42 |
1.20, 1.70 |
<0.001 |
| ICI_Class |
177 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.15 |
0.30, 3.71 |
0.823 |
| CTLA4 |
|
0.82 |
0.12, 3.61 |
0.812 |
| PDL1 |
|
1.44 |
0.59, 3.34 |
0.408 |
| cancer_group |
177 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
3.73 |
0.77, 18.2 |
0.093 |
| gu |
|
2.03 |
0.77, 5.43 |
0.151 |
| gyn |
|
2.80 |
0.49, 14.6 |
0.219 |
| other |
|
1.19 |
0.41, 3.35 |
0.739 |
| thoracic |
|
1.13 |
0.42, 3.00 |
0.806 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
177 |
1.24 |
0.79, 1.96 |
0.342 |
| male |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.26 |
0.11, 0.63 |
0.003 |
| htn |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.94 |
0.24, 4.80 |
0.934 |
| cad |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
3.30 |
1.43, 7.90 |
0.006 |
| ppi |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.96 |
0.37, 2.66 |
0.939 |
| smoking |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.07 |
0.44, 2.64 |
0.879 |
| eGFR_CRE_baseline_decrease_10 |
177 |
1.44 |
1.15, 1.86 |
0.003 |
| nephrotoxic_chemo |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.54 |
0.19, 1.51 |
0.247 |
| ICI_Class |
177 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.04 |
0.22, 4.24 |
0.961 |
| CTLA4 |
|
0.57 |
0.07, 3.21 |
0.549 |
| PDL1 |
|
1.45 |
0.50, 4.16 |
0.491 |
| cancer_group |
177 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
1.92 |
0.24, 15.4 |
0.533 |
| gu |
|
1.24 |
0.33, 4.65 |
0.747 |
| gyn |
|
2.03 |
0.22, 18.1 |
0.521 |
| other |
|
1.63 |
0.44, 5.95 |
0.456 |
| thoracic |
|
1.43 |
0.35, 5.83 |
0.616 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
177 |
1.40 |
0.87, 2.29 |
0.167 |
| male |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.20 |
0.07, 0.50 |
<0.001 |
| htn |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.76 |
0.17, 4.17 |
0.728 |
| cad |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
3.87 |
1.59, 9.98 |
0.004 |
| ppi |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.78 |
0.29, 2.23 |
0.634 |
| smoking |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.94 |
0.37, 2.37 |
0.890 |
| eGFR_CRE_baseline_decrease_10 |
177 |
1.43 |
1.13, 1.87 |
0.005 |
| Bevacizumab |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.01 |
0.31, 12.4 |
0.444 |
| Cisplatin |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.21 |
0.03, 1.17 |
0.097 |
| Carboplatin |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.83 |
0.19, 3.27 |
0.790 |
| Pemetrexed |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
4.92 |
0.87, 32.5 |
0.081 |
| Gemcitabine |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.30 |
0.29, 6.00 |
0.729 |
| Cetuximab |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.991 |
| Trastuzumab |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.993 |
| ICI_Class |
177 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
0.87 |
0.17, 3.90 |
0.860 |
| CTLA4 |
|
0.52 |
0.06, 3.17 |
0.512 |
| PDL1 |
|
1.40 |
0.45, 4.34 |
0.555 |
| cancer_group |
177 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
1.95 |
0.24, 16.3 |
0.531 |
| gu |
|
1.29 |
0.33, 5.19 |
0.716 |
| gyn |
|
0.90 |
0.06, 12.5 |
0.938 |
| other |
|
1.66 |
0.43, 6.34 |
0.455 |
| thoracic |
|
0.50 |
0.07, 2.70 |
0.437 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
177 |
1.23 |
0.78, 1.94 |
0.368 |
| male |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.27 |
0.11, 0.64 |
0.004 |
| htn |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.91 |
0.23, 4.65 |
0.902 |
| cad |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
3.30 |
1.43, 7.92 |
0.006 |
| ppi |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.95 |
0.36, 2.63 |
0.914 |
| smoking |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.03 |
0.42, 2.56 |
0.957 |
| eGFR_CRE_baseline_decrease_10 |
177 |
1.45 |
1.15, 1.87 |
0.003 |
| nephrotoxic_chemo |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.54 |
0.19, 1.53 |
0.254 |
| statins |
177 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.40 |
0.42, 5.72 |
0.608 |
| ICI_Class |
177 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.01 |
0.21, 4.14 |
0.993 |
| CTLA4 |
|
0.57 |
0.07, 3.23 |
0.557 |
| PDL1 |
|
1.47 |
0.50, 4.22 |
0.478 |
| cancer_group |
177 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
1.86 |
0.23, 15.2 |
0.555 |
| gu |
|
1.23 |
0.33, 4.60 |
0.757 |
| gyn |
|
1.92 |
0.21, 17.3 |
0.558 |
| other |
|
1.63 |
0.44, 5.94 |
0.460 |
| thoracic |
|
1.46 |
0.35, 5.96 |
0.598 |
Fine & Grey model for all
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
2,653 |
1.14 |
1.01, 1.27 |
0.029 |
| male |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.70 |
0.54, 0.91 |
0.007 |
| Race |
2,653 |
|
|
|
| Asian |
|
— |
— |
|
| Black |
|
2.95 |
0.84, 10.3 |
0.091 |
| Other/Unknown |
|
2.31 |
0.63, 8.44 |
0.210 |
| White |
|
3.21 |
1.02, 10.1 |
0.047 |
| htn |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.08 |
0.70, 1.68 |
0.730 |
| cad |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.28 |
0.99, 1.65 |
0.060 |
| cirrhosis |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.62 |
0.31, 1.24 |
0.180 |
| ace_arb |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.53 |
1.11, 2.11 |
0.010 |
| diu |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.49 |
1.08, 2.04 |
0.014 |
| ppi |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.04 |
0.75, 1.46 |
0.800 |
| steroids |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.74 |
0.53, 1.03 |
0.072 |
| smoking |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.02 |
0.78, 1.34 |
0.860 |
| statins |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.07 |
1.39, 3.09 |
<0.001 |
| nephrotoxic_chemo |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.75 |
0.58, 0.97 |
0.028 |
| Bevacizumab |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.71 |
0.40, 1.25 |
0.230 |
| Cisplatin |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.68 |
0.44, 1.05 |
0.082 |
| Carboplatin |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.97 |
0.74, 1.28 |
0.850 |
| Pemetrexed |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.45 |
1.04, 2.03 |
0.028 |
| Gemcitabine |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.84 |
0.56, 1.27 |
0.420 |
| Cetuximab |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.29 |
0.07, 1.17 |
0.082 |
| Trastuzumab |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.80 |
0.29, 2.17 |
0.660 |
| eGFR_CRE_baseline_decrease_10 |
2,653 |
1.18 |
1.12, 1.24 |
<0.001 |
| ICI_Class |
2,653 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.33 |
0.92, 1.94 |
0.130 |
| CTLA4 |
|
0.66 |
0.30, 1.45 |
0.300 |
| PDL1 |
|
1.03 |
0.72, 1.46 |
0.880 |
| cancer_group |
2,653 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.63 |
0.40, 0.99 |
0.046 |
| gu |
|
1.28 |
0.85, 1.94 |
0.240 |
| gyn |
|
0.83 |
0.42, 1.67 |
0.610 |
| other |
|
0.46 |
0.28, 0.76 |
0.003 |
| thoracic |
|
0.80 |
0.54, 1.19 |
0.270 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
2,653 |
0.95 |
0.83, 1.09 |
0.5 |
| male |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.59 |
0.45, 0.78 |
<0.001 |
| htn |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.89 |
0.56, 1.42 |
0.6 |
| cad |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.30 |
0.98, 1.71 |
0.064 |
| ppi |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.08 |
0.76, 1.54 |
0.7 |
| smoking |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.02 |
0.77, 1.34 |
>0.9 |
| eGFR_CRE_baseline_decrease_10 |
2,653 |
1.15 |
1.08, 1.22 |
<0.001 |
| Bevacizumab |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.87 |
0.48, 1.57 |
0.7 |
| Cisplatin |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.71 |
0.46, 1.10 |
0.13 |
| Carboplatin |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.95 |
0.68, 1.33 |
0.8 |
| Pemetrexed |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.05 |
1.31, 3.23 |
0.002 |
| Gemcitabine |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.82 |
0.54, 1.23 |
0.3 |
| Cetuximab |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.60 |
0.15, 2.51 |
0.5 |
| Trastuzumab |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.01 |
0.36, 2.84 |
>0.9 |
| ICI_Class |
2,653 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.27 |
0.86, 1.87 |
0.2 |
| CTLA4 |
|
0.64 |
0.29, 1.41 |
0.3 |
| PDL1 |
|
1.12 |
0.78, 1.61 |
0.5 |
| cancer_group |
2,653 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.66 |
0.41, 1.06 |
0.088 |
| gu |
|
1.15 |
0.74, 1.79 |
0.5 |
| gyn |
|
0.69 |
0.33, 1.44 |
0.3 |
| other |
|
0.51 |
0.30, 0.88 |
0.015 |
| thoracic |
|
0.56 |
0.34, 0.93 |
0.024 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
2,653 |
0.95 |
0.83, 1.09 |
0.5 |
| male |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.59 |
0.45, 0.78 |
<0.001 |
| htn |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.90 |
0.56, 1.44 |
0.7 |
| cad |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.27 |
0.96, 1.67 |
0.092 |
| ppi |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.10 |
0.77, 1.56 |
0.6 |
| smoking |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.03 |
0.78, 1.36 |
0.8 |
| eGFR_CRE_baseline_decrease_10 |
2,653 |
1.14 |
1.07, 1.21 |
<0.001 |
| nephrotoxic_chemo |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.83 |
0.62, 1.11 |
0.2 |
| ICI_Class |
2,653 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.22 |
0.83, 1.79 |
0.3 |
| CTLA4 |
|
0.63 |
0.29, 1.38 |
0.3 |
| PDL1 |
|
1.04 |
0.72, 1.50 |
0.8 |
| cancer_group |
2,653 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.67 |
0.42, 1.07 |
0.10 |
| gu |
|
1.13 |
0.73, 1.76 |
0.6 |
| gyn |
|
0.68 |
0.33, 1.40 |
0.3 |
| other |
|
0.49 |
0.29, 0.85 |
0.010 |
| thoracic |
|
0.82 |
0.53, 1.27 |
0.4 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
2,653 |
0.93 |
0.81, 1.08 |
0.3 |
| male |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.57 |
0.43, 0.75 |
<0.001 |
| htn |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.78 |
0.50, 1.24 |
0.3 |
| cad |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.22 |
0.93, 1.61 |
0.2 |
| ppi |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.03 |
0.73, 1.47 |
0.9 |
| smoking |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.03 |
0.78, 1.36 |
0.8 |
| eGFR_CRE_baseline_decrease_10 |
2,653 |
1.13 |
1.07, 1.20 |
<0.001 |
| nephrotoxic_chemo |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.80 |
0.60, 1.08 |
0.14 |
| statins |
2,653 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.95 |
1.28, 2.97 |
0.002 |
| ICI_Class |
2,653 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.22 |
0.83, 1.79 |
0.3 |
| CTLA4 |
|
0.63 |
0.29, 1.38 |
0.3 |
| PDL1 |
|
1.04 |
0.72, 1.50 |
0.8 |
| cancer_group |
2,653 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.73 |
0.45, 1.16 |
0.2 |
| gu |
|
1.16 |
0.75, 1.80 |
0.5 |
| gyn |
|
0.75 |
0.36, 1.56 |
0.4 |
| other |
|
0.51 |
0.30, 0.87 |
0.014 |
| thoracic |
|
0.84 |
0.54, 1.29 |
0.4 |